Drug Profile
Met-RANTES
Alternative Names: Methionylated RANTES; MetRANTESLatest Information Update: 12 Mar 2008
Price :
$50
*
At a glance
- Originator Geneva Biomedical Research Institute; Merck Serono
- Class Antiasthmatics; Antirheumatics; Chemokines
- Mechanism of Action CCR1 receptor antagonists; CCR5 receptor antagonists; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Rheumatoid arthritis
Most Recent Events
- 08 Jan 2007 Serono is now called Merck Serono
- 05 Jan 2007 Serono has been acquired by Merck KGaA
- 28 Oct 2004 Data presented at the 68th Annual Scientific Meeting of the American College of Rheumatology and the 39th Annual Meeting of the Association of Rheumatology Health Professionals (ACR/ARHP-2004) have been added to the Rheumatic Disease pharmacodynamics section